查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1965875

合成干细胞市场－全球产业规模、份额、趋势、机会与预测：按应用、地区和竞争格局划分，2021-2031年

Synthetic Stem Cells Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Application (Cardiovascular Diseases, Neurological Disorders, Other Applications ), By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球合成干细胞市场预计将从 2025 年的 1,658 万美元成长到 2031 年的 3,028 万美元，复合年增长率达到 10.56%。

该市场的特点是开发生物工程系统，包括基于聚合物的微粒，旨在模拟天然干细胞的旁分泌治疗效应，而无需依赖生物组织。该领域的关键驱动因素包括消除活细胞疗法固有的致瘤风险，以及无需复杂低温运输储存的稳定储存製剂所带来的物流优势。这些优势解决了传统再生医学中面临的主要安全性和扩充性挑战，使合成替代方案成为治疗慢性退化性疾病的实用解决方案。

市场概览
预测期 2027-2031
市场规模：2025年 1658万美元
市场规模：2031年 3028万美元
复合年增长率：2026-2031年 10.56%
成长最快的细分市场 心血管疾病
最大的市场 北美洲

儘管这些非生物模拟物具有许多营运优势，但市场在监管分类方面仍面临许多挑战。监管机构难以明确界定这些非生物模拟物究竟属于医疗设备、生物製药或化合物产品。这种模糊性造成了不确定性，阻碍了核准流程，但此类创新的融资环境仍有利。根据再生医学联盟预测，到2025年，再生医学领域的整​​体投资将成长30%，凸显了支持包括合成应用在内的下一代治疗技术的强劲资金流向。

市场驱动因素

推动市场发展的主要因素是再生医学领域研发投资的激增。这为将合成干细胞技术从理论概念转化为临床应用产品提供了必要的资金。这个稳健的金融生态系统帮助生物技术公司克服了临床前检验和生产规模化等成本高昂的阶段，直接满足了推出新型非生物疗法所需的资源。例如，根据《欧洲生物技术杂誌》2025年6月报道，英国政府宣布了一项新的产业战略，承诺将在生物技术领域投入3.8亿英镑。此举旨在降低早期研发风险，并鼓励私部门参与合成再生医学解决方案的商业化，从而避免生物供应链的波动。

此外，奈米技术和合成生物学的进步正在从根本上改变市场格局，提高了生物工程细胞模拟物的精确度和有效性。这些技术突破使得建构能够精确复製复杂旁分泌讯号的聚合物基系统成为可能，有效降低了细胞疗法中常见的批次间差异。例如，英国政府科技部落格在2025年6月报道称，英国研究与创新署（UKRI）投资1亿英镑建立了六个“工程生物学任务中心”，以加速该技术在医学领域的应用。研究专业新闻也在2024年11月通报称，UKRI追加投资580万英镑，以支持产业发展，巩固合成平台作为治疗方法研发核心要素的重要性。

市场挑战

全球合成干细胞市场面临的一大挑战是监管分类的严重模糊性。由于这些生物工程系统的功能与生物製药类似，但却由聚合物等合成材料构成，监管机构难以确定它们究竟应被明确归类为医疗设备、药品或生物製药。这种不确定性迫使製造商必须应对复杂且不规范的核准流程，例如美国的指定申请程序和欧洲类似的混合评估。因此，企业必须产生大量额外的安全性和有效性数据，以满足多个监管机构的不同标准，从而显着延长研发週期并增加成本。

由于缺乏明确的法规结构，大量资金和技术专长从研发转移到合规方面，直​​接阻碍了市场扩张。这些分类争议造成的资源浪费正在减缓可储存再生医学治疗方法的商业化。根据2024年欧洲医疗技术协会（MedTech Europe）的一项调查，超过70%的先进医疗技术製造商表示，应对不断演变且复杂的监管合规框架需要投入额外的内部资源。这种营运瓶颈限制了能够进入商业化阶段的合成干细胞产品数量，儘管市场对该领域有着浓厚的兴趣，但实际上却抑制了该领域的整体成长。

市场趋势

合成干细胞与3D生物列印技术的日益融合正在革新组织工程，使其能够建构复杂且功能强大的支架材料，从而精确模拟天然细胞外基质。这一趋势的重点在于将生物工程微粒整合到可列印生物墨水中，以提高结构稳定性并精确控制生长因子的释放，这对于支持血管生成和器官再生至关重要。製造商正在加速这些协同平台的商业化进程，以克服传统水凝胶在机械和物流方面的限制。例如，BICO集团在2025年2月公布，其2024财年的年度净销售额达到19.463亿瑞典克朗，这反映了围绕合成组织模型所必需的生物融合技术的活跃发展。

同时，在消费者对符合伦理规范、非动物性生物活性成分日益增长的需求推动下，药用化妆品（化妆品与药品相结合）和抗衰老配方市场正稳步扩张。合成干细胞培养物，特别是植物来源或人工设计的仿生外泌体的干细胞培养物，被广泛应用于高性能护肤品的研发，这些产品能够提供可重复的效果，且避免了生技药品相关的监管和稳定性问题。这些合成活性成分因其保护皮肤干细胞和促进胶原蛋白生成的能力而备受推崇。为了佐证该领域的商业性潜力，欧洲化妆品协会（Cosmetics Europe）在2025年6月发布的报告显示，2024年欧洲美容和个人护理市场零售额将达到1040亿欧元，凸显了这些先进生物技术配方可应用的巨大市场规模。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球合成干细胞市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 依应用领域（心血管疾病、神经系统疾病、其他应用领域（癌症、伤口、创伤、肌肉骨骼疾病、血液系统疾病））
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美合成干细胞市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲合成干细胞市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区合成干细胞市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲合成干细胞市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲合成干细胞市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章：全球合成干细胞市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • ThermoGenesis Holdings Inc.
  • Sangamo Therapeutics, Inc.
  • Pluri Inc
  • Gamida Cell Ltd.
  • Brainstorm Cell Therapeutics Ltd.
  • Vericel Corporation
  • Lisata Therapeutics, Inc.
  • Cellular Biomedicine Group Inc.
  • Cytori Therapeutics Inc.
  • Vistagen Therapeutics, Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 23977

The Global Synthetic Stem Cells Market is projected to expand from USD 16.58 Million in 2025 to USD 30.28 Million by 2031, achieving a compound annual growth rate of 10.56%. This market is characterized by the creation of bioengineered systems, including polymer-based microparticles, which are designed to mimic the therapeutic paracrine effects of natural stem cells without relying on living biological tissue. Key drivers fueling this sector include the elimination of tumorigenic risks inherent in live cell therapies and the logistical benefits of shelf-stable formulations that avoid complex cold-chain storage. These advantages address major safety and scalability issues in traditional regenerative medicine, establishing synthetic alternatives as a viable solution for treating chronic degenerative diseases.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 16.58 Million
Market Size 2031USD 30.28 Million
CAGR 2026-203110.56%
Fastest Growing SegmentCardiovascular Diseases
Largest MarketNorth America

Despite these operational benefits, the market encounters significant obstacles regarding regulatory classification, as agencies face difficulties in definitively categorizing these non-living mimics as medical devices, biologics, or combination products. This ambiguity creates uncertainty that can impede approval processes; however, the financial landscape remains favorable for such innovation. According to the Alliance for Regenerative Medicine, the broader regenerative medicine sector saw a 30 percent increase in investment in 2025, highlighting the strong flow of capital available to support next-generation therapeutic technologies, including synthetic applications.

Market Driver

A primary catalyst for the market is the surge in research and development investment for regenerative medicine, which provides the essential capital to advance synthetic stem cell technologies from theoretical concepts to viable clinical products. This strong financial ecosystem supports biotechnology firms in navigating the expensive stages of preclinical validation and manufacturing scale-up, directly addressing the resources needed to launch novel non-living therapeutics. For example, European Biotechnology Magazine reported in June 2025 that the UK government announced a new industrial strategy committing £380 million to engineering biology, a move that de-risks early-stage development and encourages private sector involvement in commercializing synthetic regenerative solutions that avoid biological supply chain volatility.

Furthermore, advancements in nanotechnology and synthetic biology are fundamentally transforming the market by improving the precision and efficacy of bioengineered cell mimics. These technical breakthroughs enable the creation of polymer-based systems that replicate complex paracrine signaling with high consistency, effectively reducing the batch-to-batch variability common in cellular therapies. Illustrating this trend, the Government Science and Engineering Blog noted in June 2025 that UKRI invested £100 million in six Engineering Biology Mission Hubs to accelerate technology application in health sectors. Additionally, Research Professional News reported in November 2024 that UKRI invested another £5.8 million to support sector growth, ensuring synthetic platforms remain central to therapeutic development.

Market Challenge

The principal challenge obstructing the Global Synthetic Stem Cells Market is the profound ambiguity regarding regulatory classification. Because these bioengineered systems function similarly to biologics but are constructed from synthetic materials like polymers, regulatory bodies struggle to categorize them definitively as medical devices, drugs, or biologics. This uncertainty compels manufacturers to navigate complicated, non-standardized approval routes, such as the Request for Designation process in the United States or similar hybrid assessments in Europe. Consequently, companies are required to generate extensive additional safety and efficacy data to satisfy the divergent standards of multiple regulatory centers, which significantly extends development timelines and increases costs.

This lack of a clear regulatory framework directly hinders market expansion by diverting capital and technical expertise from research and development toward managing compliance hurdles. The resource drain resulting from these classification disputes slows the commercialization of shelf-stable regenerative treatments. According to MedTech Europe in 2024, over 70 percent of advanced medical technology manufacturers indicated that navigating such evolving and complex regulatory compliance frameworks necessitated the allocation of additional internal resources. This operational bottleneck restricts the volume of synthetic stem cell products reaching the commercial stage, effectively stalling the sector's overall growth despite strong financial interest.

Market Trends

The increasing integration of synthetic stem cells with 3D bioprinting technologies is revolutionizing tissue engineering by allowing for the fabrication of complex, functional scaffolds that accurately simulate natural extracellular matrices. This trend focuses on embedding bioengineered microparticles into printable bio-inks to improve structural stability and provide precise control over growth factor release, which is essential for supporting vascularization and organ regeneration. Manufacturers are increasingly commercializing these synergistic platforms to address the mechanical and logistical limitations of traditional hydrogels. As evidence of this industrial scale, BICO Group reported in February 2025 that their full-year net sales reached SEK 1,946.3 million for 2024, reflecting the substantial activity surrounding the bioconvergence technologies necessary for these synthetic tissue models.

Concurrently, the market is witnessing a robust expansion into cosmeceutical and anti-aging formulations, driven by rising consumer demand for ethical, non-animal-derived bioactive ingredients. Synthetic stem cell cultures, particularly those derived from plant sources or engineered biomimetic exosomes, are being widely adopted to create high-performance skincare products that offer reproducible potency without the regulatory and stability issues associated with human-derived biologics. These synthetic actives are valued for their ability to protect skin stem cells and stimulate collagen production. Underscoring the commercial potential of this sector, Cosmetics Europe reported in June 2025 that the European beauty and personal care market generated retail sales of €104 billion in 2024, highlighting the vast landscape available for these advanced biotechnological formulations.

Key Market Players

  • ThermoGenesis Holdings Inc.
  • Sangamo Therapeutics, Inc.
  • Pluri Inc
  • Gamida Cell Ltd.
  • Brainstorm Cell Therapeutics Ltd.
  • Vericel Corporation
  • Lisata Therapeutics, Inc.
  • Cellular Biomedicine Group Inc.
  • Cytori Therapeutics Inc.
  • Vistagen Therapeutics, Inc.

Report Scope

In this report, the Global Synthetic Stem Cells Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Synthetic Stem Cells Market, By Application

  • Cardiovascular Diseases
  • Neurological Disorders
  • Other Applications (Cancers, Wounds and Injuries, Musculoskeletal Disorders, Blood disorders)

Synthetic Stem Cells Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Synthetic Stem Cells Market.

Available Customizations:

Global Synthetic Stem Cells Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Synthetic Stem Cells Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Application (Cardiovascular Diseases, Neurological Disorders, Other Applications (Cancers, Wounds, Injuries, Musculoskeletal Disorders, Blood disorders))
    • 5.2.2. By Region
    • 5.2.3. By Company (2025)
  • 5.3. Market Map

6. North America Synthetic Stem Cells Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Application
    • 6.2.2. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Synthetic Stem Cells Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Application
    • 6.3.2. Canada Synthetic Stem Cells Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Application
    • 6.3.3. Mexico Synthetic Stem Cells Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Application

7. Europe Synthetic Stem Cells Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Application
    • 7.2.2. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Synthetic Stem Cells Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Application
    • 7.3.2. France Synthetic Stem Cells Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Application
    • 7.3.3. United Kingdom Synthetic Stem Cells Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Application
    • 7.3.4. Italy Synthetic Stem Cells Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Application
    • 7.3.5. Spain Synthetic Stem Cells Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Application

8. Asia Pacific Synthetic Stem Cells Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Application
    • 8.2.2. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Synthetic Stem Cells Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Application
    • 8.3.2. India Synthetic Stem Cells Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Application
    • 8.3.3. Japan Synthetic Stem Cells Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Application
    • 8.3.4. South Korea Synthetic Stem Cells Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Application
    • 8.3.5. Australia Synthetic Stem Cells Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Application

9. Middle East & Africa Synthetic Stem Cells Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Application
    • 9.2.2. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Synthetic Stem Cells Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Application
    • 9.3.2. UAE Synthetic Stem Cells Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Application
    • 9.3.3. South Africa Synthetic Stem Cells Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Application

10. South America Synthetic Stem Cells Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Application
    • 10.2.2. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Synthetic Stem Cells Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Application
    • 10.3.2. Colombia Synthetic Stem Cells Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Application
    • 10.3.3. Argentina Synthetic Stem Cells Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Synthetic Stem Cells Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. ThermoGenesis Holdings Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Sangamo Therapeutics, Inc.
  • 15.3. Pluri Inc
  • 15.4. Gamida Cell Ltd.
  • 15.5. Brainstorm Cell Therapeutics Ltd.
  • 15.6. Vericel Corporation
  • 15.7. Lisata Therapeutics, Inc.
  • 15.8. Cellular Biomedicine Group Inc.
  • 15.9. Cytori Therapeutics Inc.
  • 15.10. Vistagen Therapeutics, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer